目的 探討von-Hippel-Lindau（VHL）綜合征并發腎癌的臨床診斷和治療水平。 方法 回顧分析2008年9月-2008年10月分別收治的2例VHL綜合征并發雙腎多發腫瘤患者的臨床診治過程并結合文獻進行討論。 結果 2例患者均為女性。例1為36歲，因腰痛不適3個月入院。既往8年有左眼視網膜血管母細胞瘤手術史。入院后雙腎CT檢查發現雙腎腫瘤伴囊腫，考慮診斷為VHL綜合征并發雙側腎癌。患者因故拒絕手術治療，隨訪至今，患者病情無明顯變化。例2為41歲，因B型超聲發現右腎占位4年，反復肉眼血尿2年入院。4年前行小腦蚓部血管母細胞瘤切除術。入院后CT檢查顯示右腎巨大實性腫瘤伴多發囊腫，左腎多發性小的囊實性占位；胰腺多發小囊腫。診斷為VHL綜合征并發右側腎癌，行右腎根治性切除。手術后病理檢查為右腎透明細胞癌，手術后隨訪至今病情穩定。 結論 VHL綜合征并發腎癌臨床少見，若患者表現為雙側、多發性、囊實性腎腫瘤，應考慮VHL綜合征并發腎癌。及時正確診斷并根據患者病情制定個體化治療方案，盡量避免腎切除，保留腎單位，手術結合影像學觀察是主要治療策略。
Objective To assess the effectiveness and safety of YunNan BaiYao capsules in reducing bleeding quantity during TURP. Methods A double-blind randomized controlled trial was conducted. We randomly allocated 40 patients to the treatment group （ YunNan BaiYao 0.25 g capsule, 2 capsules, q. i. d. , n = 20 ） and the control group （starch capsule, 2 capsules, q. i. d. , n =20）. Patients in both groups were administered three days before operation. Average bleeding quantity, bleeding index of prostate, bleeding intension, length of stay, catheter retention time, and time of washing bladder were observed and compared. Results The average bleeding quantity, bleeding index of prostate and bleeding intension were better in the treatment group than that of the control group with significant difference （P 〈0. 05 ）. The length of stay, catheter retention time and time of washing bladder had no significant difference between the two groups （P 〉0.05）. No obvious adverse effect was observed in both groups. Conclusions YunNan BaiYao capsule can effectively reduce bleeding quantity during TURP without obvious adverse effects.